Temab-A monotherapy demonstrated antitumor activity and a manageable safety profile in patients with advanced GEA. The findings support further clinical development of Temab-A, particularly in combination with other agents to improve outcomes for patients with 2L+ GEA.
Telisotuzumab Adizutecan (ABBV-400), a Novel c-Met–Targeting Antibody-Drug Conjugate: First-in-Human Results in Advanced Gastric/Gastroesophageal Junction Cancer
John Strickler·Yasutoshi Kuboki·Jonathan E. Cohen·Francois Ghiringhelli·Manish Sharma·Chiyoe Kitagawa·Ki Hyeong Lee·Bert O'Neil·M. de Miguel·Esma Saada-Bouzid·Rui Li·Nandini Rudra-Ganguly·Adam Luo·A. Parikh·G. Morrison-Thiele·Martha Neagu Aristide·Zoë Hunter·M. Burns·Judith Raimbourg